HK1206389A1 - Methods for improving resistance to skeletal muscle fatigue - Google Patents

Methods for improving resistance to skeletal muscle fatigue Download PDF

Info

Publication number
HK1206389A1
HK1206389A1 HK15106995.5A HK15106995A HK1206389A1 HK 1206389 A1 HK1206389 A1 HK 1206389A1 HK 15106995 A HK15106995 A HK 15106995A HK 1206389 A1 HK1206389 A1 HK 1206389A1
Authority
HK
Hong Kong
Prior art keywords
methods
skeletal muscle
improving resistance
muscle fatigue
fatigue
Prior art date
Application number
HK15106995.5A
Other languages
English (en)
Chinese (zh)
Inventor
Malik Fady
R. Jasper Jeffrey
Kennedy Adam
Hwee Darren
Original Assignee
Cytokinetics, Incorporated
Malik Fady
R. Jasper Jeffrey
Kennedy Adam
Darren T. Hwee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics, Incorporated, Malik Fady, R. Jasper Jeffrey, Kennedy Adam, Darren T. Hwee filed Critical Cytokinetics, Incorporated
Publication of HK1206389A1 publication Critical patent/HK1206389A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15106995.5A 2012-04-11 2013-04-11 Methods for improving resistance to skeletal muscle fatigue HK1206389A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261623003P 2012-04-11 2012-04-11
US61/623,003 2012-04-11
US201261646842P 2012-05-14 2012-05-14
US61/646,842 2012-05-14
US201261693061P 2012-08-24 2012-08-24
US61/693,061 2012-08-24
US201261735809P 2012-12-11 2012-12-11
US61/735,809 2012-12-11
PCT/US2013/036114 WO2013155262A2 (en) 2012-04-11 2013-04-11 Methods for improving resistance to skeletal muscle fatigue

Publications (1)

Publication Number Publication Date
HK1206389A1 true HK1206389A1 (en) 2016-01-08

Family

ID=49328282

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106995.5A HK1206389A1 (en) 2012-04-11 2013-04-11 Methods for improving resistance to skeletal muscle fatigue

Country Status (15)

Country Link
US (2) US20150250784A1 (https=)
EP (1) EP2836590A4 (https=)
JP (2) JP6352244B2 (https=)
KR (1) KR102163931B1 (https=)
CN (2) CN104395458A (https=)
AU (3) AU2013245917A1 (https=)
BR (1) BR112014025251B1 (https=)
CA (1) CA2869675C (https=)
EA (1) EA032480B1 (https=)
HK (1) HK1206389A1 (https=)
IL (2) IL234886A (https=)
MX (1) MX2014012179A (https=)
PH (1) PH12014502286B1 (https=)
SG (2) SG11201406359TA (https=)
WO (1) WO2013155262A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
BR112014000742A2 (pt) 2011-07-13 2016-08-23 Andrew A Wolff terapia de combinação de als
JP6387360B2 (ja) 2013-03-14 2018-09-05 ノバルティス アーゲー 変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
SI3137622T1 (sl) * 2014-04-29 2022-05-31 Cytokinetics, Inc. Postopki za zmanjšanje upada vitalne kapacitete
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
JP6573618B2 (ja) * 2014-09-09 2019-09-11 アステラス製薬株式会社 尿失禁予防用及び／又は治療用新規医薬組成物
SG11201806416XA (en) 2016-02-12 2018-08-30 Astellas Pharma Inc Tetrahydroisoquinoline derivatives
WO2018011681A1 (en) 2016-07-14 2018-01-18 Pfizer Inc. Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
IL289237B2 (en) 2019-07-23 2026-03-01 Amorphical Ltd Amorphous calcium carbonate for improving athletic performance
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
US11981644B2 (en) 2020-11-06 2024-05-14 Cytokinetics, Inc. Bicyclic 1,4-diazepanones and therapeutic uses thereof
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑ｈｄａｃ６抑制劑及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005139081A (ja) * 2003-11-04 2005-06-02 Takada Seiyaku Kk ビントペロール含有製剤
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
SI2583970T1 (sl) * 2006-08-02 2016-03-31 Cytokinetics, Inc. Določene kemijske enote, sestavki in postopki, ki obsegajo imidazopirimidine
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
EP2244711A4 (en) * 2008-02-04 2011-08-24 Cytokinetics Inc CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
AR081331A1 (es) * 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
KR20160046693A (ko) * 2012-04-02 2016-04-29 싸이토키네틱스, 인코포레이티드 횡격막 기능을 향상시키는 방법들

Also Published As

Publication number Publication date
AU2019268177A1 (en) 2019-12-12
JP2018048209A (ja) 2018-03-29
PH12014502286A1 (en) 2014-12-15
CN111840294A (zh) 2020-10-30
IL250473A0 (en) 2017-03-30
US20150250784A1 (en) 2015-09-10
KR102163931B1 (ko) 2020-10-12
SG10201704166RA (en) 2017-06-29
EA032480B1 (ru) 2019-06-28
EP2836590A2 (en) 2015-02-18
IL234886A (en) 2017-02-28
PH12014502286B1 (en) 2014-12-15
EP2836590A4 (en) 2016-04-13
EA201491666A1 (ru) 2015-03-31
AU2018200930A1 (en) 2018-03-01
KR20160046694A (ko) 2016-04-29
AU2013245917A1 (en) 2014-10-23
WO2013155262A3 (en) 2013-12-27
MX2014012179A (es) 2015-07-14
JP6535727B2 (ja) 2019-06-26
JP6352244B2 (ja) 2018-07-04
BR112014025251B1 (pt) 2021-03-02
WO2013155262A2 (en) 2013-10-17
US20190167676A1 (en) 2019-06-06
JP2015516392A (ja) 2015-06-11
CN104395458A (zh) 2015-03-04
CA2869675A1 (en) 2013-10-17
CA2869675C (en) 2022-06-14
SG11201406359TA (en) 2014-11-27

Similar Documents

Publication Publication Date Title
AU2019268177A1 (en) Improving resistance to skeletal muscle fatigue
HK1211231A1 (en) Exendin-4 derivatives
WO2009089494A3 (en) Pharmaceutical compositions
HK1209785A1 (en) Compositions and methods comprising a lipolytic enzyme variant
WO2013149258A3 (en) Compositions and methods for treating or preventing metabolic syndrome disorders
WO2011083150A3 (en) Obesity small molecules
EP2629610A4 (en) METHOD AND COMPOSITIONS FOR PREVENTING AND AIDING MUSCLE FIGHTING AND FOR RECOVERING NEUROMUSCULAR SEIZABILITY AND EXHAUST AFTER TRAINING
PH12012501494A1 (en) Treatment of cardiac conditions
PH12014501108A1 (en) Anti-il-36r antibodies
ZA201402049B (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
WO2012097213A3 (en) Methods for diagnosing and treating eye-length related disorders
HK1202244A1 (en) Prebiotic formulations and methods of use
WO2011140341A3 (en) Cosmetic compositions containing acrylic thickener
WO2010008491A3 (en) Lactose compositions with decreased lactose content
WO2013086323A3 (en) Supplemented oil compositions and methods for improved health
NZ701463A (en) Anti-phytopathogenic composition
ZA201404537B (en) Method and composition for increasing the proportion of dietary ingredients that are resistant to degradation by ruminal microorganisms
EP2924072A4 (en) VIBRATION DAMAGING RUBBER COMPOSITION AND VIBRATION DAMPING RUBBER
WO2013155338A8 (en) Substituted benzamides and their uses
WO2012035032A3 (en) Taste enhancement
WO2007084861A3 (en) Xenohormesis based compositions and methods
WO2010129406A3 (en) Methods of promoting muscle growth
WO2009098355A8 (en) Novel use of probiotics
NZ733721A (en) Methods for improving resistance to skeletal muscle fatigue
HK1203379A1 (en) β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF